PCI-24781, a novel glioblastoma signature-specific HDAC inhibitor, has been shown to significantly down-regulate O6-methylguanine-DNA-methyltransferase expression, increase DNA double-strand breaks, and lead to increased apoptosis in glioblastoma cell lines. This evidence concerns the gene HDAC9 and glioblastoma.